Drug Trial Radar · NCT04336722
Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
254
Actual
Start
Jul 8, 2020
Primary completion
Jun 22, 2026
Study completion Jun 22, 2026
Sponsor
- Lead sponsor
- Albireo, an Ipsen CompanyIndustry
- Sponsor type
- Industry
- First posted
- Apr 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 111 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with biliary atresia who have undergone a Kasai hepatoportoenterostomy.
Conditions
- Biliary Atresia
Interventions
OdevixibatDrug
Odevixibat is a small molecule and selective inhibitor of IBAT.
PlaceboDrug
Placebo identical in appearance to experimental drug (odevixibat).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from randomization to first occurrence of liver transplant, or deathTime frame: From baseline to Week 104
Locations
72 sites in 19 countries. Site status is shown where the registry gives one.
Children's Hospital Los Angeles
Los Angeles, California
Stanford Children's Health
Palo Alto, California
Rady Children's Hospital
San Diego, California
UCSF Benioff Children's Hospital San Francisco
San Francisco, California
Children's Hospital Colorado
Aurora, Colorado
Nemours/Alfred I. duPont Hospital for Children
Wilmington, Delaware
Children's National Medical Center
Washington D.C., District of Columbia
University of Miami
Miami, Florida
Children's Healthcare of Atlanta - Emory University School of Medicine
Atlanta, Georgia
Ann & Robert H. Lurie Children's Hospital
Chicago, Illinois
Indiana University school of Medicine
Indianapolis, Indiana
Johns Hopkins Children's Center
Baltimore, Maryland
Boston Children's Hospital
Boston, Massachusetts
University of Michigan Children's Hospital
Ann Arbor, Michigan
Children's Mercy Hospital
Kansas City, Missouri
Washington University in St. Louis
St Louis, Missouri
NYU Grossman school of Medicine
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
NewYork-Presbyterian Morgan Stanley Children's Hospital
New York, New York
The Children's Hospital at Montefiore
The Bronx, New York
Duke Central Tower
Durham, North Carolina
Cincinnati Children's Hospital
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Oregon Health & Science University
Portland, Oregon
The Children´s Hospital of Philadelphia
Philadelphia, Pennsylvania
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
UT Southwestern Medical Center
Dallas, Texas
University of Utah
Salt Lake City, Utah
Seattle Children's Hospital
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Royal Children's Hospital
Parkville, Australia
The Children´s Hospital at Westmead
Sydney, Australia
Women's and Children's Hospital (Women's and Children's Health Network, Incorporated.)
North Adelaide, South Australia, Australia
Cliniques Universitaires Saint-Luc
Brussels, Belgium
UZ Gent
Ghent, Belgium
CHU Sainte-Justine
Montreal, Canada
The Hospital for Sick Children
Toronto, Canada
Children's Hospital of Fudan University
Shanghai, China
Guangzhou Women and Children's Medical Center
Guangzhou, Guangdong, China
Hôpital Femme Mère Enfant
Bron, France
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.